TARGAGENIX INC.
was founded in 2013 to develop novel compounds that are effective on both drug-resistant tumors and cancer stem cells. In numerous preclinical models of cancer, including colon, pancreatic, prostate, breast and lung cancers the company’s lead product SBT-1214 has shown to completely eliminate the tumor. Additional studies have shown that SBT-1214 is able to effectively down-regulate “stemness” gene expression and kill cancer stem cells. Additional chemical modifications and a novel fatty-acid based nanoemulsion formulation result in a drug that has improved pharmacokinetics and pharmacodynamics properties as well as reduced toxicity.
TARGAGENIX INC.
Industry:
Biotechnology Chemical Health Care
Founded:
2013-01-01
Address:
Stony Brook, New York, United States
Country:
United States
Website Url:
http://www.targagenix.net
Total Employee:
1+
Status:
Active
Contact:
(516) 449-8148
Total Funding:
100 K USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Apple Mobile Web Clips Icon Content Delivery Network PHP Google Cloud Sectigo SSL Sectigo Domain SSL QUIC Wix
Similar Organizations
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
D2M Biotherapeutics
D2M Biotherapeutics focuses on the development of novel immunotherapeutics.
Passage Bio
Passage Bio is a fully integrated gene therapy company developing therapies for the treatment of monogenic central nervous system diseases.
Current Employees Featured
Founder
Investors List
Accelerate New York Seed Fund
Accelerate New York Seed Fund investment in Seed Round - TargaGenix Inc.
AJI Capital
AJI Capital investment in Seed Round - TargaGenix Inc.
Official Site Inspections
http://www.targagenix.net
- Host name: 37.252.15.57
- IP address: 37.252.15.57
- Location: Netherlands
- Latitude: 52.3824
- Longitude: 4.8995
- Timezone: Europe/Amsterdam
